Oligonucleotides: Promising Therapeutics With Significant Challenges

contributed by Corden Pharma | 07/09/2018

In recent years, interest in oligonucleotide therapeutics has resurged, as new approaches, clinical applications, advances in delivery, and a deeper biological understanding of these compounds emerge. However, expectations have been largely unfulfilled, as only three oligonucleotide drugs have been approved by the FDA for use in the United States as of August 2017.

Today, close to 200 clinical trials are registered at ClinicalTrials. gov in 2017, and as of 2016, more than 10,000 patients will have been treated with oligonucleotide drugs.1 Further, more than 120 companies globally are active in therapeutic oligo development,2 with the global market for nucleic acid aptamers expected to reach about $5.4 billion by 2019.

As a result, Contract Development & Manufacturing Organizations (CDMOs) with expertise in this field, such as CordenPharma, are experiencing increased demand for these services. However, while the outlook is positive, significant challenges remain.

Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE!

Email*

Choose a password*

I have read and understand the Privacy Notice *

Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

I want to stay up to date with the "Small Molecule" field I want to stay up to date with the Cell and Gene field I want to stay up to date with the Bioprocessing field

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.